A Protein Inhibitor Of Cas9

Tech ID: 29638 / UC Case 2019-008-0

Patent Status

Country Type Number Dated Case
United States Of America Issued Patent 11,795,208 10/24/2023 2019-008
United States Of America Published Application 20210340199 11/04/2021 2019-008

Brief Description


Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR)/Cas9 nucleases, when complexed with a guide RNA, effect genome editing in a sequence-specific manner. RNA-guided Cas9 has proven to be a versatile tool for genome engineering in multiple cell types and organisms.  There is a need in the art for additional compositions and methods for controlling genome editing activity of CRISPR/Cas9.


UC Berkeley researchers have discovered a new protein that is able to inhibit the Cas9 protein from

Staphyloccocus aureus (SauCas9). SauCas9 is smaller than the frequently used Cas9 from Streptococcus pyogenes, which has a number of benefits for delivery. The inhibitor is a small protein from a phage and is capable of strongly inhibiting gene editing in human cells.

Suggested uses

  • Gene editing


  • Limiting off-target editing, or other applications where reduced activity or rapid inhibition is desired


Learn About UC TechAlerts - Save Searches and receive new technology matches


  • Doudna, Jennifer A.

Other Information

Categorized As

Additional Technologies by these Inventors